After New Cancer Vaccine Trial, Dad, 48, Is Only Cancer
TODAY.com • • health
Key Points:
- Kevin Heyink, who carries Lynch syndrome—a genetic condition increasing cancer risk—has experienced multiple family cancer losses and undergoes frequent cancer screenings due to his high risk.
- Heyink joined a preventive cancer vaccine trial in Houston aimed at training the immune system to recognize and eliminate cancer cells associated with Lynch syndrome, using a modified adenovirus vaccine developed by Nouscom.
- The phase 1b/2 trial showed the vaccine to be safe and effective in eliciting a sustained immune response, with participants developing fewer precancerous lesions and no advanced cancers during the study.
- Heyink reports remarkable results, with three consecutive clear colonoscopies after vaccination, and only mild, temporary side effects similar to those of COVID-19 vaccines.
